Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2016, Article ID 4709597, 4 pages
http://dx.doi.org/10.1155/2016/4709597
Case Report

Mifepristone Accelerates HPA Axis Recovery in Secondary Adrenal Insufficiency

Specialized Endocrine Care Center, 150 North Robertson Boulevard, Suite 210, Beverly Hills, CA 90211, USA

Received 3 May 2016; Accepted 26 June 2016

Academic Editor: Hidetoshi Ikeda

Copyright © 2016 Pejman Cohan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. M. Berr, G. Di Dalmazi, A. Osswald et al., “Time to recovery of adrenal function after curative surgery for Cushing's syndrome depends on etiology,” Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 4, pp. 1300–1308, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. L. J. Muglia, L. Jacobson, C. Luedke et al., “Corticotropin-releasing hormone links pituitary adrenocorticotropin gene expression and release during adrenal insufficiency,” Journal of Clinical Investigation, vol. 105, no. 9, pp. 1269–1277, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Oskari, K. Kimmo, C. Horacio, S. Irving, L. Tapani, and L. Pekka, “Plasma concentrations and receptor binding of RU 486 and its metabolites in humans,” Journal of Steroid Biochemistry, vol. 26, no. 2, pp. 279–284, 1987. View at Publisher · View at Google Scholar · View at Scopus
  4. R. C. Gaillard, A. Riondel, A. F. Muller, W. Herrmann, and E. E. Baulieu, “RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 12, pp. 3879–3882, 1984. View at Publisher · View at Google Scholar · View at Scopus
  5. X. Bertagna, H. Escourolle, J. L. Pinquier et al., “Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation,” Journal of Clinical Endocrinology and Metabolism, vol. 78, no. 2, pp. 375–380, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Cohan, “Pasireotide and mifepristone: new options in the medical management of cushing's disease,” Endocrine Practice, vol. 20, no. 1, pp. 84–93, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Flitsch, D. K. Lüdecke, U. J. Knappe, and W. Saeger, “Correlates of long-term hypocortisolism after transsphenoidal microsurgery for Cushing's disease,” Experimental and Clinical Endocrinology and Diabetes, vol. 107, no. 3, pp. 183–189, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Maehana, T. Tanaka, N. Itoh, N. Masumori, and T. Tsukamoto, “Clinical outcomes of surgical treatment and longitudinal non-surgical observation of patients with subclinical Cushing's syndrome and nonfunctioning adrenocortical adenoma,” Indian Journal of Urology, vol. 28, no. 2, pp. 179–183, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. R. Hermus, G. F. Pieters, G. J. Pesman, A. G. H. Smals, T. J. Benraad, and P. W. C. Kloppenborg, “Enhancement of the ACTH response to human CRH by pretreatment with the antiglucocorticoid RU-486,” European Journal of Clinical Pharmacology, vol. 31, no. 5, pp. 609–611, 1987. View at Publisher · View at Google Scholar · View at Scopus
  10. A. C. Wulsin, J. P. Herman, and M. B. Solomon, “Mifepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic-pituitary-adrenocortical axis responsiveness to stress,” Psychoneuroendocrinology, vol. 35, no. 7, pp. 1100–1112, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Fleseriu, B. M. K. Biller, J. W. Findling, M. E. Molitch, D. E. Schteingart, and C. Gross, “Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 6, pp. 2039–2049, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Pivonello, M. De Leo, A. Cozzolino, and A. Colao, “The treatment of cushing's disease,” Endocrine Reviews, vol. 36, no. 4, pp. 385–486, 2015. View at Publisher · View at Google Scholar · View at Scopus